Take a closer look at optimizing RAASi therapy by exploring the evidence and options with potassium binders.


Treating Hyperkalemia in Patients with Heart Failure: Making the Right Choices: Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy decreases cardiovascular morbidity and mortality in patients with heart failure (HF). Evidence-based HF guidelines support the titration of RAASi to achieve target doses to optimize treatment benefits.